Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131311 | 1.00 | PTGDR2 (0.73) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4121760 | 0.93 | PTGDR2 (0.69) | PTGDR2MEN1KMT2ALMNAHTT | |
| SCHEMBL4121629 | 0.93 | PTGDR2 (0.69) | PTGDR2MEN1KMT2ALMNAHTT | |
| SCHEMBL4121104 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4114652 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4122494 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4129506 | 0.92 | PTGDR2 (0.68) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4129508 | 0.92 | PTGDR2 (0.68) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4116631 | 0.92 | PTGDR2 (0.60) | PTGDR2MEN1KMT2ALMNAHTT | |
| SCHEMBL4129299 | 0.91 | PTGDR2 (0.70) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885MEN1 4611/4885KMT2A 4216/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885MEN1 4611/4885KMT2A 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.